Niagen Bioscience (NAGE) Non-Current Deffered Revenue (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of Non-Current Deffered Revenue data on file, last reported at $2.6 million in Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue changed 0.27% year-over-year to $2.6 million in Q1 2026; TTM through Mar 2026 was $2.6 million, a 0.27% change from a year earlier, with the FY2025 full-year figure at $2.7 million, up 2.85% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $2.6 million, down from $2.7 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for NAGE reached as high as $4.3 million in Q1 2022 and fell as low as $2.6 million in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $3.3 million across 5 years, with a median of $3.3 million in 2023.
• Across the five-year window, Non-Current Deffered Revenue tumbled 32.24% in 2024 and advanced 3.68% in 2025, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $4.0 million in 2022, then declined by 16.28% to $3.3 million in 2023, then slipped by 21.47% to $2.6 million in 2024, then rose by 2.85% to $2.7 million in 2025, then decreased by 3.81% to $2.6 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $2.6 million in Q1 2026, $2.7 million in Q4 2025, and $2.7 million in Q3 2025.